Fibroblast Activity and ECM Turnover: Biomarkers for Outcomes in Fibrosis and Cancer

Your details

I register for the webinar. (Participant names are not shared with other viewers.)

The Extracellular Matrix Pharmacology Congress and its industry partner, Nordic Bioscience ApS, can contact me by email with news on research, events, products, and similar. I can always withdraw my consent at any time.

Date and time

Tuesday

March

16:00 CET

Confirm sign-up

Fibroblast Activity and ECM Turnover: Biomarkers for Outcomes in Fibrosis and Cancer

Join our webinar to explore why the extracellular matrix (ECM) sits at the center of chronic disease and why fibroblast activity is emerging as a practical, quantifiable lever for prognosis and drug development across fibrosis and oncology.

We will highlight key takeaways from over 700 publications, with a focus on the most decision-relevant insights. We will also showcase registry data from Denmark documenting that:
- 4/10 individuals live with ECM changes
- 1/4 live with fibrosis
- 55% of deaths are linked to diseases involving ECM remodeling
- 40% of deaths are linked to fibrotic diseases

Learn more

Format
60-70 minutes presentation followed by 20-30 minutes of audience Q&A.

Agenda and Speakers
Welcome and framing: why ECM turnover and fibroblast activity are clinically actionable | moderator Prof. Dr. Morten Karsdal

Registry evidence and a cross-disease view: how ECM changes and fibrosis translate to outcomes Prof. Dr. Morten Karsdal

Prognostic power in chronic liver disease: ECM biomarkers with emphasis on PRO-C3 | Dr. Diana Julie Leeming

Fibroblast activity in solid tumors: CAF biology and collagen type XI, plus broader ECM proteins | Dr. Nicholas Willumsen

Live discussion and questions from the chat (30 minutes)

Expected duration
90 minutes

Share this webinar